3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
3
Stomach Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-Positive Primary Breast Cancer
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
pembrolizumab
95
Cisplatin
35
Paclitaxel
27
Carboplatin
27
Docetaxel
17
lenvatinib
15
Fluorouracil
14
Saline Solution
13
Capecitabine
12
Pemetrexed
10
Gemcitabine
10
Oxaliplatin
9
Cetuximab
7
Albumin-Bound Paclitaxel
7
olaparib
6
epacadostat
6
Bevacizumab
6
130-nm albumin-bound paclitaxel
6
Leucovorin
5
enzalutamide
4
Etoposide
4
trifluridine tipiracil drug combination
3
regorafenib
3
belzutifan
3
Prednisone
3
Irinotecan
3
Glucose
3
Dexamethasone
3
liposomal doxorubicin
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
trastuzumab deruxtecan
×
Clear all
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled